Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
Arch. endocrinol. metab. (Online)
; 65(2): 242-247, Mar.-Apr. 2021. graf
Article
ي En
| LILACS
| ID: biblio-1248808
المكتبة المسؤولة:
BR1.1
ABSTRACT
SUMMARY Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases.
النص الكامل:
1
الفهرس:
LILACS
الموضوع الرئيسي:
Thyroid Neoplasms
/
Thyroid Carcinoma, Anaplastic
/
COVID-19
المحددات:
Humans
/
Male
اللغة:
En
مجلة:
Arch. endocrinol. metab. (Online)
موضوع المجلة:
ENDOCRINOLOGIA
/
METABOLISMO
السنة:
2021
نوع:
Article